CN1200700C - 药用曲马朵盐 - Google Patents

药用曲马朵盐 Download PDF

Info

Publication number
CN1200700C
CN1200700C CNB008121591A CN00812159A CN1200700C CN 1200700 C CN1200700 C CN 1200700C CN B008121591 A CNB008121591 A CN B008121591A CN 00812159 A CN00812159 A CN 00812159A CN 1200700 C CN1200700 C CN 1200700C
Authority
CN
China
Prior art keywords
tramadol
pharmaceutical salts
medicine
application
preparation treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008121591A
Other languages
English (en)
Other versions
CN1371277A (zh
Inventor
H·库格尔曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Publication of CN1371277A publication Critical patent/CN1371277A/zh
Application granted granted Critical
Publication of CN1200700C publication Critical patent/CN1200700C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/02—Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/02—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
    • C07D291/06—Six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

本发明涉及由活性剂曲马朵和至少一种糖代用品组成的药用盐。本发明还涉及含有这些盐的药物、这些盐在制备药物中的应用和含有这些盐的给药形式。

Description

药用曲马朵盐
本发明涉及活性物质曲马朵和至少一种糖代用品的药用盐、含有这些盐的药物、这些盐在制备药物中的应用，并且涉及含有这些盐的给药形式。
***马朵一(1RS，2RS)-2-[(二甲基氨基)甲基]-1-(3-甲氧基苯基)-环己醇盐酸盐—适合用来控制强烈的和中等强度的疼痛，并且可以治疗尿失禁。US-PS-3,652,589和WO98/46216公开了活性物质曲马朵与无机酸(如硫酸、硝酸或磷酸)和有机酸(如苯甲酸、水杨酸或邻苯二甲酸)的其它盐在制备控制疼痛或治疗尿失禁的药物中的应用。
尽管该盐在疼痛控制中功效优异，但活性物质曲马朵及其速溶盐的非常苦的味道使患者无法遵从剂量指导，并且无法接受那些在他们摄取后就立刻释放出这种活性物质的药物。包衣和复合方法，如薄膜包衣的应用，可以改善味道，但却妨碍了该活性物质由药物形式中即时释放。
由于***马朵的水溶性非常好，所以缓释药物形式的制备也非常困难，并且导致需要昂贵的阻滞加工，例如缓释包衣的应用或把该活性物质包埋在缓释骨架中。
所以，本发明的目的是提供活性物质曲马朵的药用化合物，其没有曲马朵的苦味，并且与常规、广泛使用的盐(即***马朵)相比可以更加有效地缓释曲马朵。
按照本发明，该目的是通过活性物质曲马朵和至少一种糖代用品的药用盐的制备来达到。
这些盐在水和/或含水流体中的溶解度优选≤100mg/ml，特别优选≤30mg/ml且非常特别优选≤10mg/ml。
适用的糖代用品是任何酸性糖代用品，其通过产生一种带有至少一个负电荷的形式，能够与活性物质曲马朵形成盐。该糖代用品优选糖精、环己基氨基磺酸盐(酯)、乙酰舒泛或这些糖代用品的至少两种的混合物。
为了制备本发明的药用盐，使曲马朵和/或至少一种非常易溶于水的曲马朵盐与至少一种糖代用品的至少一种游离酸和/或至少一种水溶性盐反应。所述的曲马朵的盐优选与糖代用品的水溶性盐在中性pH的含水介质内反应。优选用***马朵作为所述的曲马朵的盐。所用的糖代用品的盐优选是糖精和/或环己基氨基磺酸盐和/或乙酰舒泛的钠、钾、钙或铵盐；和/或所用糖代用品的游离酸优选是糖精/环己基氨基磺酸盐和/或乙酰舒泛的游离酸。如果曲马朵自身与糖代用品的游离酸反应，他们是在有机溶剂中反应，优选在链烷醇中反应，并且特别优选在乙醇中反应。
本发明还提供药物，其中含有至少一种作为药物活性物质的本发明的曲马朵盐以及任选的其它活性物质和/或辅助物质。所述的药物适合用来控制/治疗疼痛、尿失禁、咳嗽、炎症和变应性反应、抑郁、药物和/或酒精滥用、胃炎、腹泻、心血管疾病、呼吸疾病、精神病和/或癫痫。
本发明还提供至少一种本发明的曲马朵盐在制备用于控制/治疗疼痛、尿失禁、咳嗽、炎症和变应性反应、抑郁、药物和/或酒精滥用、胃炎、腹泻、心血管疾病、呼吸疾病、精神病和/或癫痫的药物中的应用。
施用给患者的活性物质的量根据患者的体重、给药类型、适应症和疾病的严重程度而变化。通常，至少一种本发明的曲马朵盐是以其中活性物质曲马朵的含量相当于1-600mg/天的量给药。
本发明还提供含有至少一种本发明的曲马朵盐的给药形式。
曲马朵和糖代用品在本发明的药物形式或给药形式中的量的选择应使活性物质曲马朵的苦味被糖代用品的味道弥补。本发明的给药形式优选含有等摩尔量的糖代用品和曲马朵，即两种成分事实上完全为盐形式。根据所用糖代用品的甜度和/或对曲马朵的预期释放轮廓(profile)，本发明的给药形式也可以含有不同摩尔量的曲马朵和糖代用品。
本发明的给药形式可以是固体、半固体或液体，优选口服药物制剂，其除了含有活性物质曲马朵与至少一种糖代用品的盐以外，可以任选地含有其它活性物质和常规辅助物质和添加剂。
本发明的固体给药形式优选是多粒子制剂，特别优选是颗粒、微粒、微片或小丸剂的形式且填充或不填充在胶囊中，或者片剂的形式，优选快速崩解片或泡腾片，所述的片剂优选是由小丸剂压制或通过热熔挤出法制成。
如果本发明的固体给药形式用来经肠道释放活性物质，它们必须具有至少一个抵抗胃液的包衣，其溶解为pH依赖性的。由于这种包衣，该形式在通过胃时不溶解而只在肠道内释放出活性物质。
本发明的给药形式还优选配制为凝胶、口香糖、果汁，特别优选含油或含水果汁；或喷雾剂，特别优选舌下喷雾剂。
本发明的给药形式的一个经胃释放曲马朵的优选实施方式是由例如含油或含水果汁组成，其不延迟释放活性物质。
至少一种缓释包衣的应用、活性物质的盐在至少一种缓释骨架中的包埋或者它们的联合可以实现阻滞作用，并还由此进一步改进活性物质曲马朵以及任选其它活性物质的释放。
阻滞作用适宜借助于缓释包衣来完成。适用的缓释包衣包括非水溶性蜡或聚合物，例如丙烯酸树脂，优选聚(甲基)丙烯酸酯；或非水溶性纤维素，优选乙基纤维素。这些物质是现有技术已知的，如Bauer，Lehmann，Osterwald，Rothgang“berzogene Arzneiformen”(“包衣药物形式”)，Wissenschaftliche Verlagsgesellschaft mbHStuttgart，1988，自69起，其在此引入作为参考且由此构成公开内容的一部分。
为了调节活性物质的释放速率，缓释包衣除了含有非水溶性聚合物以外，可以任选地含有：至多30％(重量)的非阻滞性、水溶性的聚合物，如聚乙烯吡咯烷酮，或水溶性纤维素，优选羟丙基甲基纤维素或羟丙基纤维素；和/或亲水性成孔剂，如蔗糖、氯化钠和甘露糖醇；和/或已知的增塑剂。
为了阻滞这种活性物质的盐，本发明的给药形式也可以优选地含有存在于缓释骨架内的所述盐，优选成为均匀分布。
可使用的骨架材料是所属领域技术人员已知的生理相容性、亲水性材料。所用的亲水性骨架材料优选聚合物，并且特别优选纤维素醚、纤维素酯和/或丙烯酸树脂。所用的骨架材料非常特别优选乙基纤维素、羟丙基甲基纤维素、羟丙基纤维素、羟甲基纤维素、聚(甲基)丙烯酸和/或其衍生物，如其盐、酰胺或酯。
同样优选的骨架材料是由疏水性材料组成的那些，如疏水性聚合物、蜡、脂肪、长链脂肪酸、脂肪醇或相应的酯或醚或其混合物。所用的疏水性材料特别优选C12-C30脂肪酸一-或二甘油酯和/或C12-C30脂肪醇和/或蜡，或其混合物。
所用的缓释骨架材料也可以是所述亲水性和疏水性材料的混合物。
本发明的给药形式可以通过所属领域技术人员熟知的那些不同方法制备。这些方法是现有技术已知的，如“PharmaceuticalPelletization Technology”，Drugs and the PharmaceuticalSciences Vol 37，Verlag Marcel Decker或“Remington’sPharmaceutical Sciences”，Mack Publishing Company，Easton，Pennsylvania。将它们在此引入作为参考并由此构成公开内容的一部分。
如果本发明的给药形式如片剂或丸剂具有包衣，它们可以通过常规方法涂布，譬如通过包衣锅法，通过溶液、分散体或混悬液的喷雾，通过热熔法或通过粉末涂布法。
由本发明用来经口腔粘膜释放曲马朵的给药形式，例如由凝胶、口香糖或舌下喷雾剂，在不使用缓释骨架和/或缓释包衣的情况下获得基本上恒定的曲马朵释放。
由本发明用来经肠道释放曲马朵的给药形式，例如由胶囊、片剂、粒剂或丸剂，在不使用缓释骨架和/或缓释包衣，但使用抵抗胃液包衣的情况下同样可获得恒定的曲马朵释放。
此外，本发明的给药形式的优点在于，曲马朵的强烈苦味被同时释放的糖代用品所弥补。这提高了剂量指导的患者依从性，并使含有活性物质曲马朵的药物被更加广泛地接受。本发明的药物还适合糖尿病患者。与***马朵相比，由曲马朵和糖代用品和/或辅助物质生成的、在水中和/或含水体液中的溶解度≤100mg/ml的盐利用常规阻滞方法产生更加有效的活性物质曲马朵的阻滞作用。因此，可以更加简便、对成本更有利地制备含有本发明的这些曲马朵盐的缓释药物。这也适合于本发明的药物的其它改变方案，例如具有抵抗胃液包衣的那些方案。
曲马朵和糖代用品的盐的溶解度测定如下：
将(1RS，2RS)-2-[(二甲基氨基)甲基]-1-(3-甲氧基苯基)-环己醇和相应的糖代用品的盐置于25℃的去离子水中，使其用量(例如约1g的曲马朵糖精盐在10ml去离子水中)能够在此温度下形成饱和溶液，其在25℃下搅拌20小时后仍然饱和。任选通过预备试验可以测得曲马朵和适当糖代用品的盐的所需量。当曲马朵和适当糖代用品的未溶解盐业已沉降后，吸出澄清的上清液且以至少3000rpm的速度离心5分钟。将如此所得澄清上清液的一部分转移至HPLC样品瓶中并以***马朵作为标准测定曲马朵和适当糖代用品的盐的浓度。
本发明借助于下列实施例进行说明。说明的作用只是举例而不限定本发明的广义实质。
实施例1
为了制备曲马朵糖精盐，在加热下，将30.0g(0.1mol)***马朵和20.53g(0.1mol)糖精钠或24.13g糖精钠二水合物(0.1mol)分别完全溶于尽可能少量的水中。随后搅拌下将两种溶液混合。冷却后，只需短时间后水溶液中就可结晶出曲马朵糖精盐，通过常规方法分离且用乙醇纯化。
按照上述方法测定了如此得到的曲马朵糖精盐在水中的溶解度，结果为22.5mg/ml。
实施例2
将30.0g(0.1mol)***马朵溶于20g水，并且在搅拌下与20.13g(0.1mol)环己基氨基磺酸钠在36g水中的溶液缓慢混合。随后将所得溶液在5℃的温度下保存16小时。得到结晶形式的曲马朵环己基氨基磺酸盐，通过常规方法分离且用乙醇纯化。
实施例3
将30.0g(0.1mol)***马溶于13g水中，并且在搅拌下与20.13g(0.1mol)乙酰舒泛钾在53g水的溶液缓慢混合。随后将所得溶液在5℃的温度下保存过夜。得到结晶形式的曲马朵乙酰舒泛盐，通过常规方法分离且用乙醇纯化。
实施例4
口服凝胶的制备通过，首先在80℃下把0.33g对羟基苯甲酸甲酯、0.05g对羟基苯甲酸丙酯和75.0g木糖醇溶于197.63g净化水，随后将该混合物冷却至40℃。此后搅拌下加入0.75g曲马朵糖精盐，随后加入2g黄原胶，将该混合物进一步搅拌1小时并且补充因蒸发损失的水。冷却至室温后，在搅拌下将该混合物用0.625g柑橘矫味剂(Orange-Mandarine Flavor)10888-56(Givaudan Roure FlavorsLtd.CH 8600 Dübendorf)矫味。
实施例5
将5g粉碎口香糖物块(Popeye Amural Confections，Yorkville，Illinois，USA)在Fanta盘中加热至30-40℃。用捣棒将150mg曲马朵糖精盐掺混在该粘的口香糖物块中。在聚四氟乙烯涂层的模子中将均化的物块分为1g的部分。鉴于对比味道试验，通过相同的方法用等化学计量量的曲马朵(相当于100mg***马朵)制备口香糖。
味道试验的结果是，含有***马朵的口香糖只在短时间后就具有难以忍受的苦味并且不再能够咀嚼。含有曲马朵糖精盐的口香糖在开始时具有良好的味道并且在长时间咀嚼后仍然宜人。
实施例6
为了制备含水果汁，首先在80℃下把0.33g对羟基苯甲酸甲酯、0.05g对羟基苯甲酸丙酯和75.0g木糖醇溶于198.37g净化水，随后使该混合物冷却至40℃，搅拌下加入0.75g曲马朵糖精盐。随后加入0.25g黄原胶，将该混合物进一步搅拌1小时并补充因蒸发损失的水。冷却至室温后，搅拌下，该混合物用0.075g Tutti Frutti9/008897(Dragoco Gerberding & Co.AG，37603 Holzminden)矫味。
实施例7
为了制备含油果汁，在80℃下将0.33g对羟基苯甲酸甲酯和0.05g对羟基苯甲酸丙酯溶于209.88g的用饱和C8-10脂肪酸酯酯化的甘油。使该混合物冷却至25℃，在搅拌下将37.5g粉碎的木糖醇、1.25g高分散二氧化硅和0.75g曲马朵糖精盐悬浮在其中。在搅拌下，该混合物用0.0125g血橙9/028658(Dragoco Gerberding & Co.AG，37603 Holzminden)矫味。
实施例8
舌下喷雾剂的制备是通过，首先在80℃下把0.33g对羟基苯甲酸甲酯、0.05g对羟基苯甲酸丙酯和75.0g木糖醇溶于197.37g蒸馏水。随后使该溶液冷却至40℃且加入0.75g曲马朵糖精盐。随后加入0.15g黄原胶，将该混合物进一步搅拌1小时，并且补充因蒸发损失的水。将该溶液冷却至25℃且用0.75g的葡萄柚14391786(IFF，International Flavors & Fragrances GmbH，46446 Emmerich)矫味。

Claims (26)

1.一种曲马朵药用盐，其特征在于该曲马朵药用盐是曲马朵与至少一种糖代用品形成的。
2.按照权利要求1的曲马朵药用盐，其特征在于该盐在水和/或水性体液中的溶解度≤100mg/ml。
3.按照权利要求1的曲马朵药用盐，其特征在于该盐在水和/或水性体液中的溶解度≤30mg/ml。
4.按照权利要求1的曲马朵药用盐，其特征在于该盐在水和/或水性体液中的溶解度≤10mg/ml。
5.按照权利要求1-4任一项的曲马朵药用盐，其特征在于所述的糖代用品是糖精、环己基氨基磺酸盐或乙酰舒泛。
6.一种药物组合物，其中含有至少一种权利要求1-5任一项的曲马朵药用盐以及任选的其它活性物质和/或辅助物质。
7.按照权利要求6的药物组合物，其特征在于它们是多粒子制剂或是片剂、快速崩解片或泡腾片的形式；或是压缩为片剂的丸剂的形式。
8.按照权利要求7的药物组合物，其特征在于多粒子制剂是颗粒、微粒、微片或丸剂的形式且填充或未填充在胶囊中。
9.按照权利要求7的药物组合物，其特征在于它们具有至少一层抵抗胃液包衣。
10.按照权利要求6的药物组合物，其特征在于它们为凝胶、口香糖、果汁或喷雾剂。
11.按照权利要求10的药物组合物，其中的果汁为含油或含水果汁。
12.按照权利要求10的药物组合物，其中的喷雾剂为舌下喷雾剂。
13.按照权利要求6-9任一项的药物组合物，其特征在于它们具有至少一种缓释骨架。
14.按照权利要求6-9任一项的药物组合物，其特征在于它们具有至少一层缓释包衣。
15.至少一种按照权利要求1-5任一项的曲马朵药用盐在制备控制疼痛的药物中的应用。
16.至少一种按照权利要求1-5任一项的曲马朵药用盐在制备治疗尿失禁的药物中的应用。
17.至少一种按照权利要求1-5任一项的曲马朵药用盐在制备治疗咳嗽的药物中的应用。
18.至少一种按照权利要求1-5任一项的曲马朵药用盐在制备治疗炎症和变应性反应的药物中的应用。
19.至少一种按照权利要求1-5任一项的曲马朵药用盐在制备治疗抑郁的药物中的应用。
20.至少一种按照权利要求1-5任一项的曲马朵药用盐在制备治疗药品和/或酒精滥用的药物中的应用。
21.至少一种按照权利要求1-5任一项的曲马朵药用盐在制备治疗胃炎的药物中的应用。
22.至少一种按照权利要求1-5任一项的曲马朵药用盐在制备治疗腹泻的药物中的应用。
23.至少一种按照权利要求1-5任一项的曲马朵药用盐在制备治疗心血管疾病的药物中的应用。
24.至少一种按照权利要求1-5任一项的曲马朵药用盐在制备治疗呼吸性疾病的药物中的应用。
25.至少一种按照权利要求1-5任一项的曲马朵药用盐在制备治疗精神病的药物中的应用。
26.至少一种按照权利要求1-5任一项的曲马朵药用盐在制备治疗癫痫的药物中的应用。
CNB008121591A 1999-08-31 2000-08-03 药用曲马朵盐 Expired - Fee Related CN1200700C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19940740.1 1999-08-31
DE19940740A DE19940740A1 (de) 1999-08-31 1999-08-31 Pharmazeutische Salze

Publications (2)

Publication Number Publication Date
CN1371277A CN1371277A (zh) 2002-09-25
CN1200700C true CN1200700C (zh) 2005-05-11

Family

ID=7919846

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008121591A Expired - Fee Related CN1200700C (zh) 1999-08-31 2000-08-03 药用曲马朵盐

Country Status (32)

Country Link
US (1) US6723343B2 (zh)
EP (1) EP1207868B1 (zh)
JP (1) JP2003508429A (zh)
KR (1) KR100730502B1 (zh)
CN (1) CN1200700C (zh)
AR (1) AR025426A1 (zh)
AT (1) ATE359064T1 (zh)
AU (1) AU781852B2 (zh)
BR (1) BR0015048A (zh)
CA (1) CA2386690C (zh)
CO (1) CO5190689A1 (zh)
CY (1) CY1107675T1 (zh)
CZ (1) CZ301259B6 (zh)
DE (2) DE19940740A1 (zh)
DK (1) DK1207868T3 (zh)
ES (1) ES2284523T3 (zh)
HK (1) HK1047229B (zh)
HU (1) HUP0302131A2 (zh)
IL (2) IL148406A0 (zh)
MX (1) MXPA02002024A (zh)
MY (1) MY127683A (zh)
NO (1) NO329625B1 (zh)
NZ (1) NZ517366A (zh)
PE (1) PE20010531A1 (zh)
PL (1) PL212105B1 (zh)
PT (1) PT1207868E (zh)
RU (1) RU2292876C2 (zh)
SI (1) SI1207868T1 (zh)
SK (1) SK285987B6 (zh)
UY (1) UY26320A1 (zh)
WO (1) WO2001015682A1 (zh)
ZA (1) ZA200202536B (zh)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10108308A1 (de) * 2001-02-21 2002-08-29 Gruenenthal Gmbh Verfahren zur Isolierung und Reinigung von (1RS,2RS)-2[(Dimethylamino)methyl]-1-(3-methoxyphenyl)-cyclohexanol
US20050176790A1 (en) * 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
US20060177381A1 (en) * 2002-02-15 2006-08-10 Howard Brooks-Korn Opiopathies
US8128957B1 (en) 2002-02-21 2012-03-06 Valeant International (Barbados) Srl Modified release compositions of at least one form of tramadol
US20050182056A9 (en) * 2002-02-21 2005-08-18 Seth Pawan Modified release formulations of at least one form of tramadol
CA2476496C (en) * 2002-02-21 2009-12-15 Biovail Laboratories Inc. Controlled release dosage forms
EP1492511B3 (fr) * 2002-04-09 2012-05-02 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
EP1364649A1 (en) * 2002-05-23 2003-11-26 Cilag AG Adduct of topiramate and tramadol hydrochioride and uses thereof
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US10004729B2 (en) 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US8840928B2 (en) * 2002-07-05 2014-09-23 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
EP1594467A4 (en) * 2002-07-05 2008-10-22 Collegium Pharmaceutical Inc MISUSE OF PHARMACEUTICAL COMPOSITIONS OF OPIOIDES AND OTHER MEDICAMENTS
US8557291B2 (en) * 2002-07-05 2013-10-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
ES2407143T3 (es) * 2003-08-06 2013-06-11 Grünenthal GmbH Forma de dosificación protegida contra un posible abuso
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
HUE037643T2 (hu) 2004-06-12 2018-09-28 Collegium Pharmaceutical Inc Visszaélésre nem alkalmas gyógyszerkészítmények
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
EP1917000A2 (en) 2005-07-07 2008-05-07 Farnam Companies, Inc. Sustained release pharmaceutical compositions for highly water soluble drugs
ES2389666T3 (es) 2005-09-09 2012-10-30 Angelini Labopharm, Llc Composición de trazodona para una administración de una vez al día
EP1785412A1 (en) * 2005-11-14 2007-05-16 IPCA Laboratories Limited Tramadol recovery process
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
GB0712101D0 (en) * 2007-06-22 2007-08-01 Therapeutics Ltd E Treatment of depression
CN101918418A (zh) * 2007-12-12 2010-12-15 阿尔迪默菲克斯技术有限责任公司 替诺福韦地索普西的固体形式
CN101467984B (zh) * 2007-12-25 2012-05-23 上海医药工业研究院 一种曲马多鼻用凝胶剂及其制备方法和用途
BRPI0906467C1 (pt) 2008-01-25 2021-05-25 Gruenenthal Gmbh forma de dosagem farmacêutica com formato exterior modificado resistente à ruptura e com liberação controlada
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
LT2273983T (lt) 2008-05-09 2016-10-25 Grünenthal GmbH Tarpinės miltelių kompozicijos gamybos būdas ir galutinė kieta dozavimo forma naudojant purškalo kietinimo stadija
GB0811024D0 (en) * 2008-06-17 2008-07-23 E Therapeutics Plc Sustained release treatment of depression
US20100003322A1 (en) * 2008-07-03 2010-01-07 Lai Felix S Enteric coated hydrophobic matrix formulation
TW201105316A (en) 2009-07-22 2011-02-16 Gruenenthal Gmbh Hot-melt extruded pharmaceutical dosage form
KR101747156B1 (ko) 2009-07-22 2017-06-27 그뤼넨탈 게엠베하 산화-안정화된 탬퍼-내성 용량형
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
CN102821757B (zh) 2010-02-03 2016-01-20 格吕伦塔尔有限公司 通过挤出机制备粉末状药物组合物
RU2607499C2 (ru) 2010-09-02 2017-01-10 Грюненталь Гмбх Устойчивая к разрушению лекарственная форма, которая содержит анионный полимер
MX2013002377A (es) 2010-09-02 2013-04-29 Gruenenthal Gmbh Forma de dosificacion resistente a manipulacion que comprende una sal inorganica.
US10702485B2 (en) 2011-07-09 2020-07-07 Syntrix Biosystems Inc. Compositions and methods for overcoming resistance to tramadol
EA201400172A1 (ru) 2011-07-29 2014-06-30 Грюненталь Гмбх Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
EA201400173A1 (ru) 2011-07-29 2014-06-30 Грюненталь Гмбх Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
JP6117249B2 (ja) 2012-02-28 2017-04-19 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 薬理学的に活性な化合物および陰イオン性ポリマーを含むタンパーレジスタント剤形
JP6282261B2 (ja) 2012-04-18 2018-02-21 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 不正使用防止および過量放出防止医薬剤形
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
AR096439A1 (es) 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido que contiene una o más partículas
CA2917136C (en) 2013-07-12 2022-05-31 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
JP6480936B2 (ja) 2013-11-26 2019-03-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング クライオミリングによる粉末状医薬組成物の調製
AU2015261060A1 (en) 2014-05-12 2016-11-03 Grunenthal Gmbh Tamper resistant immediate release capsule formulation comprising Tapentadol
EA201692388A1 (ru) 2014-05-26 2017-05-31 Грюненталь Гмбх Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
US9192613B1 (en) * 2014-10-14 2015-11-24 Sapere Ip, Llc Treatment method for primary premature ejaculation
MX2017013637A (es) 2015-04-24 2018-03-08 Gruenenthal Gmbh Forma de dosificacion resistente a alteraciones con liberacion inmediata y resistencia contra la extraccion por solventes.
CA2998259A1 (en) 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
DK3562486T3 (da) 2016-12-31 2024-06-10 Bioxcel Therapeutics Inc Anvendelse af sublingual dexmedetomidin til behandling af agitation
GR1009629B (el) 2018-02-20 2019-10-25 Laboserve Φαρμακευτικη Βιομηχανια Α.Ε. Ποσιμα διαλυματα που περιλαμβανουν τραμαδολη
GR1009630B (el) 2018-03-14 2019-10-25 Laboserve Φαρμακευτικη Βιομηχανια Α.Ε. Ποσιμα διαλυματα που περιλαμβανουν τραμαδολη και ακεταμινοφαινη
CN112888431B (zh) 2018-06-27 2022-06-03 比奥克斯塞尔医疗股份有限公司 含右美托咪定的膜制剂及其制造方法
US20240024288A1 (en) 2019-07-19 2024-01-25 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054296A (en) * 1988-10-24 2000-04-25 Symbicom Ab 66 kDa antigen from Borrelia
US3652589A (en) 1967-07-27 1972-03-28 Gruenenthal Chemie 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
NZ210386A (en) * 1983-12-09 1987-11-27 Sterling Drug Inc Saccharine salts and dentrifice compositions
CA1260941A (en) * 1983-12-09 1989-09-26 Sanofi Bis¬4-(substituted-amino)-1-pyridinium|alkane saccharin salts and process of preparation thereof
MX9205106A (es) * 1991-09-06 1993-05-01 Johnson & Johnson Composiciones que comprenden un material de tramadol y cualquiera de codeina, oxicodona o hidrocodona y su uso
US5837277A (en) * 1992-06-04 1998-11-17 Smithkline Beecham Corporation Palatable pharmaceutical compositions
US5330760A (en) * 1992-08-27 1994-07-19 Sterling Winthrop Inc. Effervescent antacid
DE19530575A1 (de) * 1995-08-19 1997-02-20 Gruenenthal Gmbh Schnell zerfallende Arzneiform von Tramadol oder einem Tramadolsalz
US5919826A (en) * 1996-10-24 1999-07-06 Algos Pharmaceutical Corporation Method of alleviating pain
JP4085433B2 (ja) * 1997-04-11 2008-05-14 日本新薬株式会社 頻尿・尿失禁治療剤
ATE284211T1 (de) * 1997-11-06 2004-12-15 Lannacher Heilmittel Orale retard-präparation enthaltend tramadol sowie verfahren zu ihrer herstellung
CN1348363A (zh) * 1998-08-27 2002-05-08 布里斯托尔-米尔斯·斯奎布公司 新的药物盐形式
US6165512A (en) * 1998-10-30 2000-12-26 Fuisz Technologies Ltd. Dosage forms containing taste masked active agents
MXPA02001820A (es) * 1999-08-20 2003-07-14 Johnson & Johnson Composicion que comprende un material de tramadol y un farmaco anticonvulsivo.
DE19940944B4 (de) * 1999-08-31 2006-10-12 Grünenthal GmbH Retardierte, orale, pharmazeutische Darreichungsformen
BR0013825A (pt) * 1999-08-31 2002-07-23 Gruenenthal Chemie Formas de apresentação de tramadol
PE20020322A1 (es) * 2000-08-18 2002-05-10 Pharmacia Corp Formulacion oral de rapida disolucion de un inhibidor de la ciclooxigenasa 2

Also Published As

Publication number Publication date
US6723343B2 (en) 2004-04-20
WO2001015682A1 (de) 2001-03-08
PL354238A1 (en) 2003-12-29
PT1207868E (pt) 2007-05-31
MY127683A (en) 2006-12-29
NO329625B1 (no) 2010-11-22
IL148406A0 (en) 2002-09-12
NZ517366A (en) 2004-07-30
JP2003508429A (ja) 2003-03-04
CN1371277A (zh) 2002-09-25
MXPA02002024A (es) 2002-08-20
ATE359064T1 (de) 2007-05-15
SK285987B6 (sk) 2008-01-07
CZ2002674A3 (cs) 2002-05-15
DE19940740A1 (de) 2001-03-01
SK2352002A3 (en) 2002-07-02
CY1107675T1 (el) 2013-04-18
EP1207868A1 (de) 2002-05-29
AR025426A1 (es) 2002-11-27
RU2002106748A (ru) 2004-01-10
UY26320A1 (es) 2000-10-31
ZA200202536B (en) 2003-09-23
AU781852B2 (en) 2005-06-16
NO20020974D0 (no) 2002-02-27
KR100730502B1 (ko) 2007-06-22
CA2386690C (en) 2009-02-10
CA2386690A1 (en) 2001-03-08
CZ301259B6 (cs) 2009-12-23
PE20010531A1 (es) 2001-06-16
CO5190689A1 (es) 2002-08-29
ES2284523T3 (es) 2007-11-16
RU2292876C2 (ru) 2007-02-10
IL148406A (en) 2007-06-03
US20030158242A1 (en) 2003-08-21
PL212105B1 (pl) 2012-08-31
BR0015048A (pt) 2003-04-29
HK1047229B (zh) 2007-11-23
KR20020025240A (ko) 2002-04-03
SI1207868T1 (sl) 2007-08-31
HK1047229A1 (en) 2003-02-14
DE50014244D1 (de) 2007-05-24
DK1207868T3 (da) 2007-09-03
NO20020974L (no) 2002-02-27
EP1207868B1 (de) 2007-04-11
AU6992100A (en) 2001-03-26
HUP0302131A2 (hu) 2003-12-29

Similar Documents

Publication Publication Date Title
CN1200700C (zh) 药用曲马朵盐
FR2572282A1 (fr) Formulations a liberation progressive, procede pour leur preparation et compositions les renfermant
JP2011116781A (ja) 脳梗塞の予防及び治療用医薬品の製造におけるｌ−ブチルフタリドの使用
AT409083B (de) Pharmazeutische, tolperison enthaltende zubereitung zur oralen verabreichung
CA2781436A1 (en) Arachidonic acid analogs and methods for analgesic treatment using same
EP1513500A2 (de) Pharmazeutiche zubereitungen zur oralen anwendung enthaltend wirkstoffbeladene ionentauscherharze sowie strukturviskose gelbildner als verdicker
CN1145586A (zh) 含药物/聚合物复合物的味掩蔽组合物
RU2205640C1 (ru) Стабильный фармацевтический состав, содержащий мексидол
WO2003059323A2 (de) Stabile salze von o-acetylsalicylsäure mit basischen aminosäuren ii
WO2003086356A1 (en) Diphenhydramine tannate solid dose compositions and methods of use
CN1965878A (zh) 含乙酰谷酰胺和红花有效成分的药物组合物及其制剂
CA2684171C (fr) Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-4-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens
CN101077340B (zh) 促渗形巴布剂基质
CN115006342A (zh) 一种抗高尿酸活性组分及其应用方法
CN111714503A (zh) 包含重酒石酸去氧肾上腺素和阿司匹林的复方固体组合物及其制剂和用途
CN1370534A (zh) 一种治疗多囊肾病的药物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20050511

Termination date: 20120803